Edaravone (Radicava) is a prescription medication used to slow the progression of amyotrophic lateral sclerosis (ALS) by acting as a neuroprotective free radical scavenger.
It is a free radical scavenger and antioxidant.
It helps to reduce oxidative stress, that contributes to neuron damage and death in ALS (and in acute ischemic stroke, for which it is also used in some countries like Japan).
It is administered either via intravenous (IV) infusion or taken orally as a suspension.
Edaravone is believed to reduce oxidative stress and protect nerve cells from damage, though its exact mechanism is not fully understood.
The exact mechanism in ALS is not fully understood, but it is believed to protect motor neurons by scavenging harmful reactive oxygen species,like hydroxyl radicals and peroxynitrite.
It is not a cure for ALS but can help delay the worsening of symptoms.
Dosage & Administration: It is taken in specific cycles.
For the IV form, this means a 14-day daily dosing cycle followed by a 14-day drug-free period, then 10 days of dosing out of 14 for subsequent cycles.
The oral version follows the same rigorous dosing schedule but is taken at home.
Edaravone contains sodium bisulfite, it can cause severe allergic reactions (including anaphylaxis) in patients with sulfite allergies, particularly those with asthma.
Other common side effects include bruising, walking/balance difficulties, headaches, fatigue, constipation and skin irritation or hives.
Serious risks are less common but can include allergic reactions or issues related to infusion.